Skip to main content
. Author manuscript; available in PMC: 2019 Mar 7.
Published in final edited form as: Prostate. 2018 Mar 24;78(9):655–663. doi: 10.1002/pros.23494

FIGURE 5.

FIGURE 5

A, Differential uptake by PC-3 human prostate cancer cells of 500nM FITC-HSA at 4 h vs 500 nM FITC-HSA-maleimide at 1 h. Blue fluorescence is due to DAPI staining of DNA and Green fluorescence is due to fluorescein-HSA-maleimide uptake. B, Dose-Response of LNCaP and PC-3 human prostate cancer cells to 5 day of fluorescein-HSA-maleimide as evaluate percent viability compared to untreated control cells.